Status:
COMPLETED
Oral Ghrelin Agonist in Healthy Subjects
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Healthy Subjects
Eligibility:
MALE
18-30 years
Phase:
PHASE1
Brief Summary
EP01572 is a peptidomimetic growth hormone secretagogue, which has potent GH-releasing activity after intravenous administration.It is an analogue of the natural compound ghrelin. Since an oral delive...
Detailed Description
EP01572 willbe given orally to 36 male subjects; the treatment will consist of one oral dose of either EP01572 or placebo (0.005, 0.05 and 0.5 mg/kg body weight). Subjects will receive one dose of EP0...
Eligibility Criteria
Inclusion
- Healthy males
Exclusion
- Females
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
End Date :
July 1 2006
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00377377
Start Date
November 1 2005
End Date
July 1 2006
Last Update
May 3 2007
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.